Quarterly ResultMay 6, 2026, 04:14 PM
Arcutis Q1 Product Revenue $105.4M, Net Loss Narrows to $11.3M
AI Summary
Arcutis Biotherapeutics reported strong first-quarter 2026 financial results, with product revenue increasing significantly and net loss narrowing. The company achieved positive net cash flow from operating activities for the quarter, a substantial improvement from the prior year. This performance was supported by the commercialization of ZORYVE across various formulations and indications, including recent launches for atopic dermatitis and scalp & body psoriasis. Arcutis also initiated a Phase 1a/1b clinical trial for ARQ-234 in atopic dermatitis, triggering a $10.0 million milestone payment.
Key Highlights
- Product revenue, net, increased to $105.4 million in Q1 2026, up from $63.8 million in Q1 2025.
- Net loss narrowed to $11.3 million in Q1 2026, compared to $25.1 million in Q1 2025.
- Achieved positive net cash flow from operating activities of $2.2 million in Q1 2026, reversing a $30.4 million outflow in Q1 2025.
- Research and development expenses rose to $30.6 million in Q1 2026 from $17.5 million in Q1 2025, including a $10.0 million milestone.
- Selling, general, and administrative expenses increased to $74.1 million in Q1 2026 from $64.0 million in Q1 2025.
- Total current assets grew to $438.1 million as of March 31, 2026, from $411.2 million at December 31, 2025.
- Initiated a Phase 1a/1b clinical trial for ARQ-234 for moderate-to-severe atopic dermatitis in March 2026.
- ZORYVE cream 0.05% for Atopic Dermatitis (2-5 yrs) commercially launched in October 2025.
Price Impact
More from ARQT